DRH1 – a novel blood-based HPV tumour marker

Human papillomavirus (HPV) and HPV-associated tumour vaccines.

EPCR: a novel marker of cultured cord blood HSCs.

These studies build on 2 prior observations, that exposure of CB-derived CD34 cells to UM171 leads to a rapid induction of EPCR expression both at the messenger RNA and protein levels and that EPCR expression can be used to identify murine HSCs, the latter finding suggesting that EPCR may be used similarly in the human setting. Identifying methods to quickly assess expansion of human HSCs ex vi...

Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker

BACKGROUND Foetal antigen 2 (FA-2), first isolated in the amniotic fluid, was shown to be the circulating form of the aminopropeptide of the alpha 1 chain of procollagen type I. Serum concentrations of FA-2 appeared to be elevated in a number of disorders of bone metabolism. This paper is the first report of its role as a marker of bone metabolism in metastatic breast cancer. METHODS Serum FA...

S47. Tumour infiltrating lymphocytes - a predictive marker?

Results We showed that tumors from human colorectal cancer with a high density of infiltrating memory and effector memory T-cells (TEM) are less likely to disseminate to lymphovascular and perineural structures and to regional lymph-nodes. We showed that the combination of immune parameters associating the nature, the density, the functional orientation and the location of immune cells within t...

Use of thyroglobulin as a tumour marker

It is worthwhile to measure serum thyroglobulin (TG) level in thyroid cancer before subjecting patients to surgery for two reasons. Firstly, if the level is high, it may give a clue to the local and metastatic tumour burden at presentation; secondly, if the level is normal, it identifies the patients who are unlikely to show rising TG levels in the presence of thyroid cancer. Those who have hig...